Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia

Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia

Background: Tocilizumab is a well-practiced strategy to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy. However, varied efficiency in CRS mitigation by tocilizumab has been reported to highlight affecting variables such as tumor types and timing of the...

Full description

Bibliographic Details
Main Authors: Chengxin Luan, Haixia Wang, Junjie Zhou, Zhangbiao Long, Xin Chen, Xiaowen Chen, Jing Ni, Zhengqi Huang, Ruixiang Xia, Jian Ge
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2023-09-01
Series:Biomedical Technology
Subjects:
Chimeric antigen receptor T cell therapy
Cytokine release syndrome
Tocilizumab
Diffuse large B-cell lymphoma (DLBCL)
Acute lymphoblastic leukemia (ALL)
Online Access:http://www.sciencedirect.com/science/article/pii/S2949723X23000028

Internet

http://www.sciencedirect.com/science/article/pii/S2949723X23000028

Similar Items